Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

Is Alprazolam recalled?

Yes — there is an active recall. 4 ongoing FDA recalls mention Alprazolam (33 total). Check the affected lots below.

Most common reason: Cross-contamination (13 of these recalls)

Recalls are matched by product description. A recall usually affects specific lots, not every package of Alprazolam. “Active” means an FDA recall is still ongoing; “closed” means it was terminated or completed. Checked against openFDA on Oct 10, 2026.

Alprazolam recalls in 2026

1 initiated in 2026, 33 in total — newest first
Class II · Moderate risk

Xanax XR

Failed Dissolution Specifications

Ongoing Dissolution failure Viatris, Inc. NDC 58151-506-91 D-0444-2026
Class II · Moderate risk

Alprazolam Tab

CGMP Deviations: Downstream recall from Breckenridge Pharmaceuticals, Inc due to potential risk of Cross Contamination.

Terminated Cross-contamination Preferred Pharmaceuticals, Inc. NDC 68788-7596-3 D-0506-2023
Class II · Moderate risk

Alprazolam Tab

CGMP Deviations: Downstream recall from Breckenridge Pharmaceuticals, Inc due to potential risk of Cross Contamination.

Terminated Cross-contamination Preferred Pharmaceuticals, Inc. NDC 68788-7595-3 D-0505-2023
Class II · Moderate risk

Alprazolam Tab

CGMP Deviations: Downstream recall from Breckenridge Pharmaceuticals, Inc due to potential risk of Cross Contamination.

Terminated Cross-contamination Preferred Pharmaceuticals, Inc. NDC 68788-7594-3 D-0504-2023
Class II · Moderate risk

Alprazolam C-IV

CGMP Deviations: Repackaging firm recalling due to potential product cross contamination concerns at the manufacturer.

Ongoing Cross-contamination Direct Rx NDC 72189-121-60 D-0509-2023
Class II · Moderate risk

Alprazolam C-IV

CGMP Deviations: Repackaging firm recalling due to potential product cross contamination concerns at the manufacturer.

Ongoing Cross-contamination Direct Rx NDC 72189-213-30 D-0508-2023
Class II · Moderate risk

Alprazolam C-IV

CGMP Deviations: Repackaging firm recalling due to potential product cross contamination concerns at the manufacturer.

Ongoing Cross-contamination Direct Rx NDC 72189-0240-30 D-0507-2023
Class II · Moderate risk

Alprazolam Tablets

CGMP Deviations: Potential risk of Cross Contamination

Terminated Cross-contamination Breckenridge Pharmaceutical, Inc NDC 51991-0707-01 D-0461-2023
Class II · Moderate risk

Alprazolam Tablets

CGMP Deviations: Potential risk of Cross Contamination

Terminated Cross-contamination Breckenridge Pharmaceutical, Inc NDC 51991-0706-01 D-0460-2023
Class II · Moderate risk

Alprazolam Tablets

CGMP Deviations: Potential risk of Cross Contamination

Terminated Cross-contamination Breckenridge Pharmaceutical, Inc NDC 51991-0705-01 D-0459-2023
Class II · Moderate risk

Alprazolam Tablets

CGMP Deviations: Potential risk of Cross Contamination

Terminated Cross-contamination Breckenridge Pharmaceutical, Inc NDC 51991-0704-01 D-0458-2023
Class II · Moderate risk

Xanax XR (alprazolam)

Failed Dissolution Specifications: low out of specification results for dissolution.

Terminated Dissolution failure Viatris Inc NDC 0009-0068-07 D-0854-2022
Class II · Moderate risk

Alprazolam C-IV 2 mg

CGMP Deviations: The Recall is due to the potential cross-contamination at the contract manufacturer (Ultra Tab Laboratories Inc.)

Terminated Cross-contamination Direct Rx NDC 72189-0058-60 D-0651-2022
Class II · Moderate risk

Alprazolam Tablets

CGMP Deviation: Potential cross-contamination with other drug substance during the manufacturing process.

Terminated Cross-contamination Golden State Medical Supply Inc. NDC 60429-504-18 D-0654-2022
Class II · Moderate risk

Alprazolam Tablets

Failed Impurities/Degradation Specifications: Elevated levels of a known impurity detected during 6-month RT stability interval.

Terminated Impurity / degradation Mylan Institutional, Inc. (d.b.a. UDL Laboratories) D-1013-2019
Class II · Moderate risk

Alprazolam Tablets

Failed Impurities/Degradation Specifications: Out-of-specification result for an unknown impurity.

Terminated Impurity / degradation The Harvard Drug Group NDC 0904-5858-61 D-0013-2018
Class III · Low risk

Xanax (Alprazolam)

Labeling: Missing Label-Primary packaging label (i.e. blister card) is blank and contains no product information (e.g. product name, strength, lot number, expiry).

Terminated Labeling / mix-up Mckesson Packaging Services NDC 63739-669-10 D-1527-2016